Professor Harry Iland

Clinical Professor
Medicine, Central Clinical School

Telephone +61 2 9515 7451
Fax +61 2 9515 6698

Map

Research interests

His main interests have encompassed molecular abnormalities in haematological malignancies, and he established one of the earliest molecular diagnostic laboratories for haematological malignancy in Australia. In the last few years he has been responsible for the Australasian Leukaemia and Lymphoma Group's clinical trial program in acute promyelocytic leukaemia (APL), and has combined this with an active laboratory program in the molecular analysis of APL cells. His laboratory has also established molecular assays relevant for patients with idiopathic hypereosinophilic syndrome / chronic eosinophilic leukaemia.

International links

United Kingdom

(Kings College London) Prof David Grimwade - retinoic acid receptor ligand binding domain mutational analysis in relapsed acute promyelocytic leukaemia

United States

(Memorial Sloan Kettering Cancer Center) Professor Martin Tallman - planning a multi-cooperative group trial in acute promyelocytic leukemia

United States

(Robert H. Lurie Comprehensive Cancer Center, Northwestern University) Dr Jessica Altman - planning a multi-cooperative group trial in acute promyelocytic leukemia

Selected grants

2009

  • A new Laser Microdissection Microscope with a unique pressure catapulting technique allows isolation of pure samples for subsequent downstream molecular analyses; Halliday G, Morris B, Mason R, Murphy C, Bishop A, Leamey C, Joshua D, Lee C, Iland H, Pamphlett R, Richardson D, King N, Hunt N, Arnold J, Morris M, Protti D; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2007

  • PHERAstar and POLARstar Optima multi-functional plate readers with robotic high throughput screening system for multi-disciplinary cancer research; Halliday G, Ho J, Conigrave A, Iland H, Lee C, Joshua D, Cook D, Richardson D, Reichardt J, Grau G, Lovejoy D, Hunt N, King N, Mason R, Murphy C, Sharland A, Assinder S, Dong Q, Bishop A; Cancer Institute New South Wales/Infrastructure Grant.

2004

  • Zinc finger transcription factors in human cancers: normal and aberrant functions; Iland H, Rasko J; Cure Cancer Australia Foundation/Research Support.

1998

  • Automated quantitation of gene expression using an applied biosystems model 7700 sequence detector; Bishop A, McCaughan G, Garsia R, Iland H, Halliday G; Wellcome Trust (UK)/Major Equipment Awards for Biomedical Research in Australia.

Selected publications

Download citations: PDF RTF Endnote

Edited Books

  • Iland, H., Hertzberg, M., Marlton, P. (2005). Myeloid Leukemia: Methods and Protocols. Humana Press.

Book Chapters

  • Iland, H. (2000). Detection of minimal residual disease in hematologic malignancies by molecular technology. In Kerry Atkinson (Eds.), Clinical Bone Marrow and Blood Stem Cell Transplantation, (pp. 1659-1675). New York, USA: Cambridge University Press.

Journals

  • Iland, H., Wei, A., Seymour, J. (2014). Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice & Research: Clinical Haematology, 27(1), 39-52. [More Information]
  • Iland, H., Seymour, J., Wei, A. (2014). Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion In Hematology, 21(4), 102-113. [More Information]
  • Bhattacharyya, A., Cooper, A., Hong, A., Iland, H., McNeil, C. (2014). Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma. Internal Medicine Journal, 44(2), 207-208. [More Information]
  • Firkin, F., Iland, H. (2013). Arsenic: an old enemy now turned friend. Leukemia and Lymphoma, 54(9), 1864-1866. [More Information]
  • Khoo, T., Catalano, A., Supple, S., Chong, L., Yeoh, S., Yeung, S., Iland, H. (2013). Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leukemia and lymphoma, 54(1), 186-188. [More Information]
  • Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal, 43(5), 484-494. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Iland, H., Seymour, J. (2013). Role of arsenic trioxide in acute promyelocytic leukemia. Current Treatment Options in Oncology, 14(2), 170-184. [More Information]
  • Iland, H., Bradstock, K., Supple, S., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al (2012). All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8), 1570-1580. [More Information]
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal, 42(11), 1179-1186. [More Information]
  • Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, J., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica: the hematology journal, 97(1), 64-72. [More Information]
  • Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., et al (2012). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica: the hematology journal, 97(2), 227-234. [More Information]
  • de Zwaan, S., Iland, H., Damian, D. (2009). Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. The Australasian Journal of Dermatology, 50(1), 56-59. [More Information]
  • Losco, P., Brown, R., Iland, H., Uhr, E., Lee, L., Joshua, D. (2007). An evaluation of the technical performance and clinical applications of the Beckman Coulter Access Erythropoietin immunoassay. Australian Journal of Medical Science, 28(4), 139-144.
  • Young, G., Iland, H. (2007). Clinical perspectives in lymphoma. Internal Medicine Journal, 37(7), 478-484. [More Information]
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Catalano, A., Dawson, M., Somana, K., Opat, S., Schwarer, A., Campbell, L., Iland, H. (2007). The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood, 110(12), 4073-4076. [More Information]
  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]
  • Catalano, A., Iland, H. (2005). Molecular biology of lymphoma in the microarray era. Pathology, 37(6), 508-522. [More Information]
  • Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Diagnosis and molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR to quantify PML/RAR alpha fusion transcripts. Clinical Chemistry (Washington, DC), 48(8), 1338-1343.
  • Stevenson, W., Vincent, P., Iland, H. (2002). Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation. Leukemia and lymphoma, 43(11), 2221-2224.
  • Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Molecular monitoring of acute promyelocytic leukemia by DzyNA reverse transcription-PCR. Clinical Chemistry (Washington, DC), 48(10), 1858-1860.
  • Iland, H., Barnett, M., Pollard, J., Supple, S. (2001). A spontaneous novel XK gene mutation in a patient with McLeod syndrome. British Journal of Haematology, 115, 369-372.

2014

  • Iland, H., Wei, A., Seymour, J. (2014). Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best Practice & Research: Clinical Haematology, 27(1), 39-52. [More Information]
  • Iland, H., Seymour, J., Wei, A. (2014). Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion In Hematology, 21(4), 102-113. [More Information]
  • Bhattacharyya, A., Cooper, A., Hong, A., Iland, H., McNeil, C. (2014). Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma. Internal Medicine Journal, 44(2), 207-208. [More Information]

2013

  • Firkin, F., Iland, H. (2013). Arsenic: an old enemy now turned friend. Leukemia and Lymphoma, 54(9), 1864-1866. [More Information]
  • Khoo, T., Catalano, A., Supple, S., Chong, L., Yeoh, S., Yeung, S., Iland, H. (2013). Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leukemia and lymphoma, 54(1), 186-188. [More Information]
  • Gibson, J., Iland, H., Larsen, S., Brown, C., Joshua, D. (2013). Leukaemias into the 21st century - part 2: the chronic leukaemias. Internal Medicine Journal, 43(5), 484-494. [More Information]
  • Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer Journal, 3, 1-7. [More Information]
  • Iland, H., Seymour, J. (2013). Role of arsenic trioxide in acute promyelocytic leukemia. Current Treatment Options in Oncology, 14(2), 170-184. [More Information]

2012

  • Iland, H., Bradstock, K., Supple, S., Catalano, A., Collins, M., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Hugman, A., et al (2012). All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 120(8), 1570-1580. [More Information]
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal, 42(11), 1179-1186. [More Information]
  • Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, J., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica: the hematology journal, 97(1), 64-72. [More Information]
  • Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., et al (2012). Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica: the hematology journal, 97(2), 227-234. [More Information]

2009

  • de Zwaan, S., Iland, H., Damian, D. (2009). Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. The Australasian Journal of Dermatology, 50(1), 56-59. [More Information]

2007

  • Losco, P., Brown, R., Iland, H., Uhr, E., Lee, L., Joshua, D. (2007). An evaluation of the technical performance and clinical applications of the Beckman Coulter Access Erythropoietin immunoassay. Australian Journal of Medical Science, 28(4), 139-144.
  • Young, G., Iland, H. (2007). Clinical perspectives in lymphoma. Internal Medicine Journal, 37(7), 478-484. [More Information]
  • Sanders, J., Crawford, B., Gibson, J., Ho, J., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International Journal of Laboratory Hematology, 29(5), 395-397. [More Information]
  • Catalano, A., Dawson, M., Somana, K., Opat, S., Schwarer, A., Campbell, L., Iland, H. (2007). The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood, 110(12), 4073-4076. [More Information]

2006

  • Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, J. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? American Journal Of Hematology, 81(2), 110-114. [More Information]

2005

  • Catalano, A., Iland, H. (2005). Molecular biology of lymphoma in the microarray era. Pathology, 37(6), 508-522. [More Information]
  • Iland, H., Hertzberg, M., Marlton, P. (2005). Myeloid Leukemia: Methods and Protocols. Humana Press.

2002

  • Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Diagnosis and molecular monitoring of acute promyelocytic leukemia using DzyNA reverse transcription-PCR to quantify PML/RAR alpha fusion transcripts. Clinical Chemistry (Washington, DC), 48(8), 1338-1343.
  • Stevenson, W., Vincent, P., Iland, H. (2002). Disseminated granulocytic sarcoma treated with allogeneic peripheral blood stem-cell transplantation. Leukemia and lymphoma, 43(11), 2221-2224.
  • Applegate, T., Iland, H., Mokany, E., Todd, A. (2002). Molecular monitoring of acute promyelocytic leukemia by DzyNA reverse transcription-PCR. Clinical Chemistry (Washington, DC), 48(10), 1858-1860.

2001

  • Iland, H., Barnett, M., Pollard, J., Supple, S. (2001). A spontaneous novel XK gene mutation in a patient with McLeod syndrome. British Journal of Haematology, 115, 369-372.

2000

  • Iland, H. (2000). Detection of minimal residual disease in hematologic malignancies by molecular technology. In Kerry Atkinson (Eds.), Clinical Bone Marrow and Blood Stem Cell Transplantation, (pp. 1659-1675). New York, USA: Cambridge University Press.

To update your profile click here. For support on your academic profile contact .